These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26818147)

  • 1. Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.
    Vitrano A; Calvaruso G; Tesé L; Gioia F; Cassarà F; Campisi S; Butera F; Commendatore V; Rizzo M; Santoro V; Cigna V; Quota A; Bagnato S; Argento C; Fidone C; Schembari D; Gerardi C; Barbiera F; Bellisssima G; Giugno G; Polizzi G; Rosso R; Abbate G; Caruso V; Chiodi E; Gamberini MR; Giorgi B; Putti MC; Filosa A; De Ritis MR; Oliva E; Arcadi N; Fustaneo M; Mistretta L; Di Maggio R; Sacco M; Veronica DS; Giangreco A; Maggio A
    Eur J Haematol; 2016 Oct; 97(4):361-70. PubMed ID: 26818147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK
    Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
    Badawy SM; Liem RI; Rigsby CK; Labotka RJ; DeFreitas RA; Thompson AA
    Br J Haematol; 2016 Nov; 175(4):705-713. PubMed ID: 27507431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET.
    Vitrano A; Sacco M; Rosso R; Quota A; Fiorino D; Oliva E; Gerardi C; Roccamo G; Spadola V; Filosa A; Tesé L; Calvaruso G; Pitrolo L; Mistretta L; Cassarà F; Di Maggio R; Maggio A
    Eur J Haematol; 2018 Feb; 100(2):124-130. PubMed ID: 29094403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
    Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
    Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.
    Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D
    Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation.
    Jarisch A; Salzmann-Manrique E; Cario H; Grosse R; Soerensen J; Fischer R; Schulz A; Hammerstingl R; Wunderlich A; Bader P
    Eur J Haematol; 2018 Dec; 101(6):791-797. PubMed ID: 30187571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of iron overload in hemoglobinopathies.
    Allali S; de Montalembert M; Brousse V; Chalumeau M; Karim Z
    Transfus Clin Biol; 2017 Sep; 24(3):223-226. PubMed ID: 28673501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients.
    Pakbaz Z; Fischer R; Fung E; Nielsen P; Harmatz P; Vichinsky E
    Pediatr Blood Cancer; 2007 Sep; 49(3):329-32. PubMed ID: 17554789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serial serum ferritin measurements and liver iron concentration assessed by MRI in adult transfused patients with sickle cell disease.
    Tsitsikas DA; Nzouakou R; Ameen V; Sirigireddy B; Amos RJ
    Eur J Haematol; 2014 Feb; 92(2):164-7. PubMed ID: 24175986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.
    Piga A; Longo F; Musallam KM; Cappellini MD; Forni GL; Quarta G; Chiavilli F; Commendatore F; Mulas S; Caruso V; Galanello R
    Br J Haematol; 2013 Jun; 161(6):872-83. PubMed ID: 23600689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of non-invasive assessment in prediction of preclinical cardiac affection in multi-transfused thalassaemia major patients.
    Said Othman KM; Elshazly SA; Heiba NM
    Hematology; 2014 Oct; 19(7):380-7. PubMed ID: 24225039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statural Growth and Prevalence of Endocrinopathies in Relation to Liver Iron Content (LIC) in Adult Patients with Beta Thalassemia Major (BTM) and Sickle Cell Disease (SCD).
    Yassin MA; Soliman AT; De Sanctis V; Abdula MAJ; Riaz LM; Ghori FF; Yousaf A; Nashwan AJ; Abusamaan S; Moustafa A; Kohla S; Soliman DS
    Acta Biomed; 2018 Feb; 89(2-S):33-40. PubMed ID: 29451227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferiprone as an oral iron chelator in sickle cell disease.
    Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
    Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
    Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT
    Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
    Wood JC; Pressel S; Rogers ZR; Odame I; Kwiatkowski JL; Lee MT; Owen WC; Cohen AR; St Pierre T; Heeney MM; Schultz WH; Davis BR; Ware RE;
    Am J Hematol; 2015 Sep; 90(9):806-10. PubMed ID: 26087998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia.
    Taher A; Musallam KM; El Rassi F; Duca L; Inati A; Koussa S; Cappellini MD
    Br J Haematol; 2009 Sep; 146(5):569-72. PubMed ID: 19604239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.